The University of Zimbabwe-University of California, San Francisco Collaborative Research Programme (UZUCSF), in collaboration with the University of California, San Francisco (UCSF), is the site of a well-established, large Clinical Trials Unit (CTU) with 4 Clinical Research Sites (CRSs), covering 6 distinct geographic locations within and surrounding Harare, Zimbabwe. Experience gained from leadership and participation in 4 Division of AIDS (DAIDS) Networks (HPTN, MTN, ACTG, IMPAACT), positions the CTU to continue its contribution to the global understanding of HIV epidemiology and pathogenesis by serving as a center of research excellence in the prevention and control of HIV and AIDS. Utilizing the expertise of our international and local complement of investigators and highly trained and experienced research personnel, the CTU will accomplish this through completion of the following Specific Aims: 1.a. Identifying, screening, enrolling, and retaining existing and new at-risk populations in an environment of declining prevalence and incidence, in the following mission-specific domains of scientific priority of the 4 future NIAID-sponsored Networks: i) Adult HIV Therapeutic Strategies, including HIV cure, noninfectious comorbidities, and the infectious co-morbidities of hepatitis and tuberculosis;ii) Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations;iii) Integrated HIV Prevention Strategies;and iv) Microbicide Strategies to Prevent HIV infections, and 1.b. Contributing to the scientific leadership of the 4 future NIAID-sponsored Networks. 2. Utilizing an increasingly efficient and sophisticated centralized administrative structure to support the uninterrupted execution of protocols across 4 restructured CRSs, laboratory, and pharmacy components. 3. Leveraging the integral relationships developed with the CTU's community partners and diverse stakeholders to disseminate research findings and translate research results into evidence-based best practices and policies at the local, regional, and international levels.

Public Health Relevance

The CTU's implementation of protocols across the 4 Networks may produce results that translate to policies within Zimbabwe and internationally to reduce HIV incidence and prevalence. The CTU anticipates that this new evidence will further inform policies to reduce the Zimbabwean HIV incidence from its current 3% to 2%;reduce current HIV prevalence from 13% to 7.5%;reduce HIV vertical transmission from the current 14% to <5%;and reduce TB incidence from 633 per 100,000 persons to 200 per 100,000.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069436-08
Application #
8608833
Study Section
Special Emphasis Panel (ZAI1-SV-A (S1))
Program Officer
Germuga, Donna E
Project Start
2007-03-01
Project End
2020-11-30
Budget Start
2013-12-10
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$6,381,501
Indirect Cost
$116,745
Name
University of California San Francisco
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Shivakoti, Rupak; Christian, Parul; Yang, Wei-Teng et al. (2016) Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr 35:183-9
Shivakoti, Rupak; Yang, Wei-Teng; Berendes, Sima et al. (2016) Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings. J Infect Dis 213:1074-8
Mirembe, Brenda G; Kelly, Clifton W; Mgodi, Nyaradzo et al. (2016) Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr 71:287-94
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
Balkus, Jennifer E; Brown, Elizabeth R; Hillier, Sharon L et al. (2016) Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception 93:25-31
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8
La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58
Fogel, Jessica M; Hudelson, Sarah E; Ou, San-San et al. (2016) Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 72:304-9
van der Straten, Ariane; Brown, Elizabeth R; Marrazzo, Jeanne M et al. (2016) Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc 19:20642
Hosseinipour, Mina C; Bisson, Gregory P; Miyahara, Sachiko et al. (2016) Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 387:1198-209

Showing the most recent 10 out of 29 publications